Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.

British Journal of Cancer
U GraevenW Schmiegel

Abstract

The humanised anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active against pancreatic cancer in preclinical studies. This phase I study assessed the safety and potential benefit of combined treatment with matuzumab and standard-dose gemcitabine. Three groups of chemotherapy-naive advanced pancreatic adenocarcinoma patients (n=17) received escalating doses of matuzumab (400 mg weekly, 800 mg biweekly, or 800 mg weekly) and gemcitabine (1000 mg m-2 weekly in weeks 1-3 of each 4-week cycle). Toxicity, antitumour activity, pharmacokinetic (PK) parameters, and pharmacodynamic (PD) markers in skin biopsies were evaluated. Severe treatment-related toxicities were limited to grade 3 neutropenia (n=3), leucopenia (n=1), and decreased white blood cell count (n=1). Common study drug-related adverse events were skin toxicities (grade 2=6, grade 1=7) and fever (grade 1=4). Matuzumab inhibited phosphorylated EGFR and affected receptor-dependent signalling and transduction; effects were seen even in the lowest-dose group. Pharmacokinetic data were consistent with results of matuzumab monotherapy. Partial response (PR) or stable disease occurred in eight of 12 evaluated patients (66.7%), wit...Continue Reading

References

Jan 1, 1992·The Journal of Pathology·N R LemoineW J Gullick
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·W SchmiegelE V Jensen
Apr 14, 1999·CA: a Cancer Journal for Clinicians·D M ParkinJ Ferlay
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Nov 8, 2002·Seminars in Oncology·Henry Q Xiong, James L Abbruzzese
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Udo VanhoeferJosé Baselga
Apr 3, 2004·Cancer Treatment Reviews·Sufi Mary Thomas, Jennifer Rubin Grandis
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry Q XiongJames L Abbruzzese
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoinette R TanSandra M Swain

❮ Previous
Next ❯

Citations

Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrew M ScottLloyd J Old
Mar 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A KlegerT Seufferlein
Jan 8, 2008·World Journal of Gastroenterology : WJG·Michael HöpfnerHans Scherübl
Aug 30, 2008·British Medical Bulletin·S A DanoviN R Lemoine
Mar 24, 2009·Molecular Medicine·Andreas A Argyriou, Haralabos P Kalofonos
Jan 5, 2010·Immunotherapy·Zhi-Qiang Huang, Donald J Buchsbaum
Aug 19, 2011·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Kimberley S SamkoeBrian W Pogue
Jan 27, 2012·DNA and Cell Biology·Kobra Omidfar, Zaynab Shirvani
Oct 23, 2012·Cancer Metastasis Reviews·Cindy NeuzilletEric Raymond
May 29, 2007·Oncogene·I Zafir-LavieY Reiter
Feb 15, 2007·Expert Opinion on Therapeutic Targets·David BerzHoward Safran
May 1, 2007·Expert Opinion on Therapeutic Targets·Jen Jen Yeh, Channing J Der
Feb 17, 2009·Expert Opinion on Biological Therapy·Dimiter V Tassev, Nai-Kong V Cheung
Jun 9, 2007·Expert Opinion on Biological Therapy·Barbara Burtness
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Francesco CaponigroRosario Vincenzo Iaffaioli
Jun 4, 2008·Expert Opinion on Pharmacotherapy·M Wasif Saif
Sep 20, 2006·Expert Opinion on Therapeutic Targets·Ann Marie Egloff, Jennifer Grandis
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Amedeo AmedeiDomenico Prisco
Mar 20, 2013·BioMed Research International·Elena NiccolaiAmedeo Amedei
Mar 4, 2017·Expert Opinion on Emerging Drugs·Kalliopi AndrikouStefano Cascinu
Aug 23, 2008·American Journal of Surgery·Daniel Borja-CachoSelwyn Maurice Vickers
May 19, 2010·Expert Review of Clinical Immunology·Peter J BugelskiEsther Bouman-Thio
Aug 30, 2008·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Han Hsi Wong, Nicholas R Lemoine
Dec 22, 2007·Acta Oncologica·Fernando RiveraRaul Marquez
Mar 24, 2011·Experimental Biology and Medicine·Juna Lee, Chulso Moon
Oct 4, 2006·Nature Reviews. Drug Discovery·Christopher A McCullochHani El-Gabalawy
Sep 4, 2007·Journal of Clinical Pharmacology·Kathleen Seitz, Honghui Zhou
Nov 23, 2007·International Journal of Cancer. Journal International Du Cancer·Takeshi YoshidaKazuhiko Nakagawa
Dec 7, 2006·Cancer Chemotherapy and Pharmacology·Tomislav DragovichAmita Patnaik
Oct 9, 2007·Nature Biotechnology·Christopher Thomas Scott
Apr 23, 2008·Cancer Metastasis Reviews·Alexios StrimpakosKostas N Syrigos
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·Soley Bayraktar, Caio M Rocha-Lima
Jun 7, 2008·Expert Review of Anticancer Therapy·Michel Vulfovich, Caio Rocha-Lima
Oct 16, 2009·Expert Review of Anticancer Therapy·R Pamela Mackenzie, A David McCollum
Feb 5, 2016·Journal of Cancer Research and Clinical Oncology·Elias KotteasKonstantinos Syrigos

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
biopsy
light microscopy
enzyme-linked immunosorbent assay
biopsies

Software Mentioned

Kinetica

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.